StockNews.AI
TMO
StockNews.AI
17 days

Thermo Fisher's NGS Assay Receives FDA Approval as a Companion Diagnostic for ZEGFROVY and for Tumor Profiling

1. FDA approves Thermo Fisher's Oncomine™ Dx Express Test for tumor profiling. 2. The test enhances decentralized clinical settings with next-gen sequencing capabilities.

+0.37%Current Return
VS
+0.79%S&P 500
$427.7607/03 08:22 AM EDTEvent Start

$429.3307/04 02:19 PM EDTLatest Updated
2 mins saved
Full Article

FAQ

Why Bullish?

This approval may boost Thermo Fisher's revenue from diagnostic tests, similar to past FDA approvals that resulted in significant stock rallies for similar companies, like Illumina post-Gene sequencing approvals.

How important is it?

The approval indicates increased market potential and confidence in Thermo Fisher's products, aligning with growth trends in personalized medicine and diagnostics.

Why Short Term?

Immediate sales growth expected from the launched test, as new FDA approvals typically lead to quick market adoption and increased demand.

Related Companies

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the U.S. Food and Drug Administration (FDA) has approved the Oncomine™ Dx Express Test on the Ion Torrent™ Genexus™ Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay for use as a companion diagnostic (CDx) for Dizal's ZEGFROVY® (sunvozertinib) and in tumor profiling. This approval brings rapid next-generation sequencing (NGS) to decentralized clinical settings closer to.

Related News